Home Logon FTA Investment Managers Blog Subscribe About Us Contact Us

Search by Ticker, Keyword or CUSIP       
Blog Home
Bob Carey
Chief Market Strategist
X •  LinkedIn

  Biotechnology Stocks Still At Reasonable Valuation Levels
Posted Under: Sectors
Supporting Image for Blog Post

View from the Observation Deck  
  1. From 3/9/09 through 9/27/17 (current bull market), the S&P 500 Biotechnology Index posted a cumulative total return of 437.45%, compared to 337.92% for the S&P 500 Health Care Index and 344.09% for the S&P 500 Index, according to Bloomberg.
  2. The all-time high for the S&P 500 Biotechnology Index was established on 7/20/15 at a reading of 4,371.83. The index's P/E ratio stood at 22.80 at the end of July 2015. The index began to sell-off after it peaked on 7/20/15. 
  3. On 9/21/15, presidential candidate Hillary Clinton spoke out on drug pricing practices after two companies were called out for "price gouging," according to Forbes. Her pledge to keep therapeutic costs in check if elected was a bit of a drag on the performance of the drug makers, particularly biotechnology stocks (see chart), in our opinion. 
  4. From 9/21/15 through 11/3/16, the low for the index in 2016 and just prior to the presidential election on 11/8/16, the S&P 500 Biotechnology Index declined by 15.84% on a total return basis, according to Bloomberg. The sell-off from the peak (7/20/15) through 11/3/16 was 26.76%. 
  5. Donald Trump's election victory coupled with the inability of the Republicans in Congress to repeal and replace the Affordable Care Act ("Obamacare") has helped temper some of the concern over the federal government's involvement in the issue of  prescription drug prices, in our opinion.
  6. From 11/8/16 through 9/27/17, the S&P 500 Biotechnology Index was up 29.73%, according to Bloomberg. While the index has rallied significantly, it closed 9/27/17 at a reading of 4,185.20, still below its all-time high of 4,371.83, according to Bloomberg.
  7. The annual earnings on the S&P 500 Biotechnology Index increased from $59.63 per share in 2009 to $235.06 per share in 2016. Bloomberg's consensus estimates for 2017 and 2018 were $262.00 and $278.16 per share, respectively, as of 9/28/17. 
This chart is for illustrative purposes only and not indicative of any actual investment. The illustration excludes the effects of taxes and brokerage commissions and other expenses incurred when investing. There can be no assurance that any of the projections cited will occur. Investors cannot invest directly in an index. The S&P 500 Biotechnology Index is a capitalization-weighted index comprised of S&P 500 constituents in the biotechnology sector. The S&P 500 Health Care Index is a capitalization-weighted index comprised of S&P 500 constituents operating in the health care sector. The S&P 500 Index is a capitalization-weighted index comprised of 500 stocks (currently 505) used to measure large-cap U.S. stock market performance.

To Download a PDF of this post, please click here.
Posted on Thursday, September 28, 2017 @ 2:39 PM • Post Link Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts
Market Commentary and Analysis
Market Commentary Video
Monthly Talking Points
Quarterly Newsletter
Market Observations
Subscribe To Receive Email

S&P 500 Index Top-Line Growth Estimates
This Homebuilder Index Is Still Well Below Its All-Time High
S&P 500 Index’s Dividend Payout Still Trending Higher
Why the Market Continues to Go Up
The S&P 500 Index Just Set Another All-Time Closing High
A Snapshot Of Dividend-Payers & Non-Payers In The S&P 500 Index
S&P 500 Index Stock Prices Relative To Their 52-Week Highs
A Snapshot of Bond Valuations
How The S&P 500 Index Has Performed Since The Brexit Vote
Some Insight Into The S&P 500 Index Dividend Payout
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
Follow First Trust:  
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2024 All rights reserved.